Literature DB >> 20821055

Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).

Hsiang-Yu Lin1, Cheng-Hung Huang, Hsiao-Chi Yu, Kah-Wai Chong, Ju-Hui Hsu, Pi-Chang Lee, Kang-Hsiang Cheng, Chuan-Chi Chiang, Huey-Jane Ho, Shuan-Pei Lin, Shih-Jen Chen, Po-Kang Lin, Dau-Ming Niu.   

Abstract

Newborn screening for Fabry disease in Taiwan Chinese has revealed a high incidence of the late-onset GLA mutation IVS4 + 919G→A (∼1 in 1,500-1,600 males). We studied 94 adults with this mutation [22 men, 72 women; mean age: men 57.8 ± 6.0 (range 42-68), women 39.1 ± 14.1 years (range 19-82)]. Plasma α-galactosidase A activity assay was 10.4 ± 11.2% of normal in the men and 48.6 ± 19.5% of normal in the women. Echocardiography in 90 of the adults revealed left ventricular hypertrophy (LVH) in 19 (21%), including 14 of 21 men (67%) and 5 of 69 women (7%). Microalbuminuria, based on the urine albumin-to-creatinine ratio measured on at least two occasions, was present in 17 of 86 subjects (20%) (men: 5/20, 25%; women 12/66, 18%). At least one ocular manifestation consistent with Fabry disease was present in 41 of 52 subjects (79%) who underwent ophthalmologic examination, including 8 (15%) with conjunctival vessel tortuosity, 15 (29%) with cornea verticillata, 10 (19%) with Fabry cataract, and 34 (65%) with retinal vessel tortuosity. Among subjects over 40 years of age, men were more likely than women to have LVH [14/21 (67%) vs 5/25 (20%), p < 0.001]. Cardiovascular, renal and ocular abnormalities are highly prevalent in adult Taiwan Chinese subjects with the Fabry mutation IVS4 + 919G→A. Our findings contribute to the limited understanding of the course of this late-onset disease variant and underscore the need for close follow up in such patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20821055     DOI: 10.1007/s10545-010-9166-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  28 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

3.  Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.

Authors:  M Tanaka; T Ohashi; M Kobayashi; Y Eto; N Miyamura; K Nishida; E Araki; K Itoh; K Matsushita; M Hara; K Kuwahara; T Nakano; N Yasumoto; H Nonoguchi; K Tomita
Journal:  Clin Nephrol       Date:  2005-10       Impact factor: 0.975

4.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

5.  Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy.

Authors:  Lorenzo Monserrat; Juan Ramón Gimeno-Blanes; Francisco Marín; Manuel Hermida-Prieto; Antonio García-Honrubia; Inmaculada Pérez; Xusto Fernández; Rosario de Nicolas; Gonzalo de la Morena; Eduardo Payá; Jordi Yagüe; Jesús Egido
Journal:  J Am Coll Cardiol       Date:  2007-12-18       Impact factor: 24.094

6.  Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients.

Authors:  Christophe Orssaud; Jean Dufier; Dominique Germain
Journal:  Ophthalmic Genet       Date:  2003-09       Impact factor: 1.803

7.  Results of a nationwide screening for Anderson-Fabry disease among dialysis patients.

Authors:  Peter Kotanko; Reinhard Kramar; Danijela Devrnja; Eduard Paschke; Till Voigtländer; Martin Auinger; Severo Pagliardini; Marco Spada; Klaus Demmelbauer; Matthias Lorenz; Anna-Christine Hauser; Hans-Jörg Kofler; Karl Lhotta; Ulrich Neyer; Wolfgang Pronai; Manfred Wallner; Clemens Wieser; Martin Wiesholzer; Herbert Zodl; Manuela Födinger; Gere Sunder-Plassmann
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

8.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

Authors:  Shoichiro Nakao; Chihaya Kodama; Toshihiro Takenaka; Akihiro Tanaka; Yuichiro Yasumoto; Aichi Yoshida; Tamotsu Kanzaki; Annette L D Enriquez; Christine M Eng; Hiromitsu Tanaka; Chuwa Tei; Robert J Desnick
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

9.  Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study.

Authors:  D Levy; D D Savage; R J Garrison; K M Anderson; W B Kannel; W P Castelli
Journal:  Am J Cardiol       Date:  1987-04-15       Impact factor: 2.778

10.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

View more
  14 in total

1.  Age at First Cardiac Symptoms in Fabry Disease: Association with a Chinese Hotspot Fabry Mutation (IVS4+919G>A), Classical Fabry Mutations, and Sex in a Taiwanese Population from the Fabry Outcome Survey (FOS).

Authors:  Hao-Chuan Liu; Amandine Perrin; Ting-Rong Hsu; Chia-Feng Yang; Hsiang-Yu Lin; Wen-Chung Yu; Dau-Ming Niu
Journal:  JIMD Rep       Date:  2015-03-12

Review 2.  Cell microencapsulation: a potential tool for the treatment of neuronopathic lysosomal storage diseases.

Authors:  Ursula Matte; Valeska Lizzi Lagranha; Talita Giacomet de Carvalho; Fabiana Quoos Mayer; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-05-26       Impact factor: 4.982

3.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.

Authors:  Laura M Amendola; Gail P Jarvik; Michael C Leo; Heather M McLaughlin; Yassmine Akkari; Michelle D Amaral; Jonathan S Berg; Sawona Biswas; Kevin M Bowling; Laura K Conlin; Greg M Cooper; Michael O Dorschner; Matthew C Dulik; Arezou A Ghazani; Rajarshi Ghosh; Robert C Green; Ragan Hart; Carrie Horton; Jennifer J Johnston; Matthew S Lebo; Aleksandar Milosavljevic; Jeffrey Ou; Christine M Pak; Ronak Y Patel; Sumit Punj; Carolyn Sue Richards; Joseph Salama; Natasha T Strande; Yaping Yang; Sharon E Plon; Leslie G Biesecker; Heidi L Rehm
Journal:  Am J Hum Genet       Date:  2016-05-12       Impact factor: 11.025

4.  Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert J Desnick; Wuh-Liang Hwu
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

5.  Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.

Authors:  Xuantong Dai; Xue Zong; Xiaoxia Pan; Wei Lu; Geng-Ru Jiang; Fujun Lin
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

6.  Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.

Authors:  Yin-Hsiu Chien; Olaf A Bodamer; Shu-Chuan Chiang; Hermann Mascher; Christina Hung; Wuh-Liang Hwu
Journal:  J Inherit Metab Dis       Date:  2012-10-30       Impact factor: 4.982

7.  Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry.

Authors:  C Ronald Scott; Susan Elliott; Norman Buroker; Lauren I Thomas; Joan Keutzer; Michael Glass; Michael H Gelb; Frantisek Turecek
Journal:  J Pediatr       Date:  2013-03-01       Impact factor: 4.406

Review 8.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

9.  Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A).

Authors:  Ting-Rong Hsu; Shih-Hsien Sung; Fu-Pang Chang; Chia-Feng Yang; Hao-Chuan Liu; Hsiang-Yu Lin; Chun-Kai Huang; He-Jin Gao; Yu-Hsiu Huang; Hsuan-Chieh Liao; Pi-Chang Lee; An-Hang Yang; Chuan-Chi Chiang; Ching-Yuang Lin; Wen-Chung Yu; Dau-Ming Niu
Journal:  Orphanet J Rare Dis       Date:  2014-07-01       Impact factor: 4.123

10.  Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A).

Authors:  Hsiang-Yu Lin; Hao-Chuan Liu; Yu-Hsiu Huang; Hsuan-Chieh Liao; Ting-Rong Hsu; Chia-I Shen; Shao-Tzu Li; Cheng-Fang Li; Li-Hong Lee; Pi-Chang Lee; Chun-Kai Huang; Chuan-Chi Chiang; Ching-Yuang Lin; Shuan-Pei Lin; Dau-Ming Niu
Journal:  BMJ Open       Date:  2013-07-16       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.